Diagnostic implications of transcription factor pax 2 protein and dtransmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms

Ruta Gupta, Bonnie Balzer, Maria Picken, Adeboye O. Osunkoya, Tanuja Shet, Randa Alsabeh, Daniel Luthringer, Gladell P. Paner, Mahul Amin

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Pax 2, expressed by metanephric mesenchyme is vital for renal tubule formation and development. Carbonic anhydrase IX (CA IX) is implicated in cell proliferation, adhesion, and invasion. Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants. Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX. Clear cell RCC (28/30, 93%), oncocytoma (17/17, 100%), papillary RCC (16/30, 53%), and mucinous tubular spindle cell carcinoma (3/4, 75%) demonstrated nuclear immunoreactivity with Pax 2, whereas the other subtypes were nonreactive. Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal tumors with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive. This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative). CA IX expression has potential diagnostic implications including (i) clear cell RCC (positive) versus chromophobe RCC (negative) and (ii) urothelial carcinoma (positive) versus collecting duct carcinoma (negative). These antibodies may reliably discriminate between clinically significant subtypes of RCC with overlapping cytoarchitectural features.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalAmerican Journal of Surgical Pathology
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

Fingerprint

Paired Box Transcription Factors
Glandular and Epithelial Neoplasms
Kidney Neoplasms
Renal Cell Carcinoma
Enzymes
Proteins
Carcinoma
Oxyphilic Adenoma
Kidney
Carbonic Anhydrase IX
Neoplasms

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery
  • Medicine(all)

Cite this

Diagnostic implications of transcription factor pax 2 protein and dtransmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. / Gupta, Ruta; Balzer, Bonnie; Picken, Maria; Osunkoya, Adeboye O.; Shet, Tanuja; Alsabeh, Randa; Luthringer, Daniel; Paner, Gladell P.; Amin, Mahul.

In: American Journal of Surgical Pathology, Vol. 33, No. 2, 01.02.2009, p. 241-247.

Research output: Contribution to journalArticle

Gupta, Ruta ; Balzer, Bonnie ; Picken, Maria ; Osunkoya, Adeboye O. ; Shet, Tanuja ; Alsabeh, Randa ; Luthringer, Daniel ; Paner, Gladell P. ; Amin, Mahul. / Diagnostic implications of transcription factor pax 2 protein and dtransmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. In: American Journal of Surgical Pathology. 2009 ; Vol. 33, No. 2. pp. 241-247.
@article{a57523e444214b17ae53997efa71c824,
title = "Diagnostic implications of transcription factor pax 2 protein and dtransmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms",
abstract = "Pax 2, expressed by metanephric mesenchyme is vital for renal tubule formation and development. Carbonic anhydrase IX (CA IX) is implicated in cell proliferation, adhesion, and invasion. Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants. Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX. Clear cell RCC (28/30, 93{\%}), oncocytoma (17/17, 100{\%}), papillary RCC (16/30, 53{\%}), and mucinous tubular spindle cell carcinoma (3/4, 75{\%}) demonstrated nuclear immunoreactivity with Pax 2, whereas the other subtypes were nonreactive. Clear cell RCC (30/30, 100{\%}), urothelial carcinoma (27/30, 90{\%}), papillary RCC (17/30, 57{\%}), and renal tumors with Xp11.2 translocation (6/15, 40{\%}) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive. This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative). CA IX expression has potential diagnostic implications including (i) clear cell RCC (positive) versus chromophobe RCC (negative) and (ii) urothelial carcinoma (positive) versus collecting duct carcinoma (negative). These antibodies may reliably discriminate between clinically significant subtypes of RCC with overlapping cytoarchitectural features.",
author = "Ruta Gupta and Bonnie Balzer and Maria Picken and Osunkoya, {Adeboye O.} and Tanuja Shet and Randa Alsabeh and Daniel Luthringer and Paner, {Gladell P.} and Mahul Amin",
year = "2009",
month = "2",
day = "1",
doi = "10.1097/PAS.0b013e318181b828",
language = "English (US)",
volume = "33",
pages = "241--247",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Diagnostic implications of transcription factor pax 2 protein and dtransmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms

AU - Gupta, Ruta

AU - Balzer, Bonnie

AU - Picken, Maria

AU - Osunkoya, Adeboye O.

AU - Shet, Tanuja

AU - Alsabeh, Randa

AU - Luthringer, Daniel

AU - Paner, Gladell P.

AU - Amin, Mahul

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Pax 2, expressed by metanephric mesenchyme is vital for renal tubule formation and development. Carbonic anhydrase IX (CA IX) is implicated in cell proliferation, adhesion, and invasion. Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants. Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX. Clear cell RCC (28/30, 93%), oncocytoma (17/17, 100%), papillary RCC (16/30, 53%), and mucinous tubular spindle cell carcinoma (3/4, 75%) demonstrated nuclear immunoreactivity with Pax 2, whereas the other subtypes were nonreactive. Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal tumors with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive. This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative). CA IX expression has potential diagnostic implications including (i) clear cell RCC (positive) versus chromophobe RCC (negative) and (ii) urothelial carcinoma (positive) versus collecting duct carcinoma (negative). These antibodies may reliably discriminate between clinically significant subtypes of RCC with overlapping cytoarchitectural features.

AB - Pax 2, expressed by metanephric mesenchyme is vital for renal tubule formation and development. Carbonic anhydrase IX (CA IX) is implicated in cell proliferation, adhesion, and invasion. Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants. Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX. Clear cell RCC (28/30, 93%), oncocytoma (17/17, 100%), papillary RCC (16/30, 53%), and mucinous tubular spindle cell carcinoma (3/4, 75%) demonstrated nuclear immunoreactivity with Pax 2, whereas the other subtypes were nonreactive. Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal tumors with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive. This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative). CA IX expression has potential diagnostic implications including (i) clear cell RCC (positive) versus chromophobe RCC (negative) and (ii) urothelial carcinoma (positive) versus collecting duct carcinoma (negative). These antibodies may reliably discriminate between clinically significant subtypes of RCC with overlapping cytoarchitectural features.

UR - http://www.scopus.com/inward/record.url?scp=60249091319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249091319&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e318181b828

DO - 10.1097/PAS.0b013e318181b828

M3 - Article

VL - 33

SP - 241

EP - 247

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 2

ER -